Compare · A vs TMO
A vs TMO
Side-by-side comparison of Agilent Technologies Inc. (A) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Industrials sector. A focuses on Biotechnology: Laboratory Analytical Instruments, while TMO focuses on Industrial Machinery/Components.
- TMO is the larger of the two at $213.42B, about 5.5x A ($39.08B).
- Over the past year, A is up 20.5% and TMO is up 23.1% - TMO leads by 2.6 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- Agilent Technologies Inc.
- Thermo Fisher Scientific Inc
- Price
- $138.35-0.25%
- $574.39-0.38%
- Market cap
- $39.08B
- $213.42B
- 1M return
- +3.73%
- +11.85%
- 1Y return
- +20.45%
- +23.08%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 1999
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 25
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest A
- Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
- Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
- Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
- Jefferies resumed coverage on Agilent with a new price target
- Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
- Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
- Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.21% to 14,108 units (SEC Form 4)
- Bernstein resumed coverage on Agilent with a new price target
- Agilent Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
Latest TMO
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- President & COO Pettiti Gianluca sold $226,000 worth of shares (400 units at $565.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,651 units (SEC Form 4)
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports Second Quarter 2026 Results
- Thermo Fisher Scientific Announces Quarterly Dividend
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Keith R. Alexandra
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Lynch Karen S